Cargando…

Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real‐world setting

[Image: see text]

Detalles Bibliográficos
Autores principales:	Papp, K.A., Gooderham, M.J., Albrecht, L.E., Raymond, M.‐A., Lynde, C.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374060/ https://www.ncbi.nlm.nih.gov/pubmed/34748637 http://dx.doi.org/10.1111/bjd.20885

Ejemplares similares

Addition of Cyclosporine to Adalimumab Improved Psoriasis And Adalimumab-Induced Injection Site Reaction
por: Nakamizo, Satoshi, et al.
Publicado: (2014)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis
por: Zhang, Si, et al.
Publicado: (2022)

Treating psoriasis with adalimumab
por: Alwawi, Eihab A, et al.
Publicado: (2008)

Real‐world effectiveness of adalimumab in patients with moderate‐to‐severe hidradenitis suppurativa: the 1‐year SOLACE study
por: Gulliver, W., et al.
Publicado: (2021)

Hidradenitis suppurativa with SAPHO syndrome maintained effectively with adalimumab, methotrexate, and intralesional corticosteroid injections
por: Crowley, Erika L, et al.
Publicado: (2018)

Hidradenitis suppurativa and adalimumab in the COVID-19 era
por: Marzano, Angelo Valerio, et al.
Publicado: (2021)

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
por: Smolen, Josef S, et al.
Publicado: (2018)

Adalimumab/methotrexate: COVID-19 infection: case report
Publicado: (2020)

Management of Crohn’s disease in poor responders to adalimumab
por: de Boer, Nanne KH, et al.
Publicado: (2014)

Adalimumab for severe psoriasis in Chilean paediatric patients()()
por: Armijo Fernandez, Daniela, et al.
Publicado: (2020)

Adalimumab for treatment of very early onset inflammatory bowel disease
por: Xie, Yao, et al.
Publicado: (2019)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

Methotrexate and Adalimumab Decrease the Serum Levels of Cardiovascular Disease Biomarkers (VCAM-1 and E-Selectin) in Plaque Psoriasis
por: Zdanowska, Natalia, et al.
Publicado: (2020)

Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007)

Adalimumab in Recalcitrant Severe Psoriasis Associated with Atopic Dermatitis
por: Yayli, Savas, et al.
Publicado: (2013)

Visual Loss Induced by Adalimumab Used for Plaque Psoriasis
por: Saffra, Norman, et al.
Publicado: (2017)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis
por: Keystone, Edward C, et al.
Publicado: (2018)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
por: Blauvelt, Andrew, et al.
Publicado: (2020)

Differing contribution of methotrexate polyglutamates to adalimumab blood levels as compared with etanercept
por: Dervieux, Thierry, et al.
Publicado: (2019)

Adalimumab/methotrexate/prednisone: Severe COVID-19 infection: case report
Publicado: (2021)

Pituitary Sarcoidosis in a Pediatric Patient Successfully Treated With Adalimumab and Methotrexate
por: Villacis-Nunez, D. Sofia, et al.
Publicado: (2021)

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
por: Burmester, Gerd R, et al.
Publicado: (2017)

Successful treatment of adalimumab-resistant palmoplantar pustulosis with secukinumab: a case report
por: Li, Qing-Yang, et al.
Publicado: (2020)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis
por: de Natividade, Natallia Barreiros, et al.
Publicado: (2017)

Real-World Outcomes of Adalimumab Treatment for Moderate and Severe Psoriasis in Korean Patients (RAPSODI Study)
por: Kim, Dong Hyun, et al.
Publicado: (2023)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial
por: Burmester, Gerd-Rűdiger, et al.
Publicado: (2015)

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
por: O’Mahony, Alison, et al.
Publicado: (2018)

Digital Vasculitis in a Patient with Rheumatoid Arthritis Responded Well to Adalimumab
por: Kobak, Senol, et al.
Publicado: (2014)

Thalamic stroke in a young adult with severe psoriasis refractory to adalimumab
por: Kadayakkara, Deepak Kana, et al.
Publicado: (2015)

Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence
por: Lombardi, G, et al.
Publicado: (2016)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Resolution of post-adalimumab vitiligo with secukinumab in a patient with psoriasis vulgaris
por: Palazzo, Giovanni
Publicado: (2020)

Rituximab-Induced Psoriasis in a Patient with Granulomatosis with Polyangitis Treated with Adalimumab
por: Alahmari, Hana S., et al.
Publicado: (2019)

The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
por: Panahi, M., et al.
Publicado: (2021)

Efficacy of Adalimumab for Nail Psoriasis During 24 Months of Continuous Therapy
por: KOKOLAKIS, Georgios, et al.
Publicado: (2020)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h1f747bmmutsj1u2k98ev2ndd7